A CASE-BASED ETHICS CURRICULUM FOR THE BIOTECH INDUSTRY

描述（申请人摘要）：该项目的总体目标是 研究和开发关于商业道德决策的教材 生物技术和基因组学产品商业化的参与者。 有四个具体目标。他们是（1）研究和确定道德 当生物技术和基因组研究被 商业化，（2）制定分析性商业道德决策 可用于制药和生物技术的模型或过程 当管理者面临这些道德和社会问题时，（3） 根据过去的经验，在商业道德方面开展全面的案例研究 制药和生物技术企业行为，以及（4）应用 这些案例研究的决策过程，作为企业如何 管理者可以将道德反思、辩论和分析纳入业务 实践开发的教育材料将促进公司决策 加强负责任地利用基因组和生物技术信息 以及从研究到上市后开发阶段的产品。结果 该研究项目将主要针对制药和 生物技术公司高管、经理、董事会成员和律师。的 详细的案例研究，通过中心之间的合作， 生物医学伦理学和商业研究生院将在 斯坦福大学的高管教育项目。这个独特的项目吸引了 来自国际商界的领导人，提供一个独特的 有机会教育决策者在生物技术和制药 行业还将提供所编写的案例研究， 斯坦福大学和其他研究生院的商业伦理课程 业务。案件材料将通过万维网分发， 最终通过传统的教科书格式。这样， 开发的材料将提供给任何对道德和 人类基因组研究商业化的社会后果。

DESCRIPTION (Applicant's Abstract): The general aim of the project is to research and develop instructional material on business ethics decision making for those involved in commercializing biotechnology and genomics products. There are four specific aims. They are (1) to research and identify the ethical and social issues that are raised when biotechnology and genomic research is commercialized, (2) to develop an analytical business ethics decision making model or process that can be used by pharmaceutical and biotechnology corporations when their managers face these ethical and social issues, (3) to develop comprehensive case studies in business ethics based on past pharmaceutical and biotechnology corporate behavior, and (4) to apply the decision making process to these case studies as examples of how corporate managers can incorporate ethical reflection, debate, and analysis into business practices. The educational materials developed will foster corporate decision making that enhances responsible use of genomic and biotechnology information and products from research to postmarketing phases of development. The results of this research project will be directed primarily to pharmaceutical and biotechnology corporate executives, managers, board members and attorneys. The detailed case studies developed through collaboration between the Center for Biomedical Ethics and the Graduate School of Business will be utilized within Stanford University's Executive Education Program. This unique program attracts leaders from the international business community, providing a singular opportunity to educate decision makers in the biotechnology and pharmaceutical industries. The case studies developed will also be available to augment business ethics curricula at Stanford University and of other graduate schools of business. Case material will be distributed via the World Wide Web and eventually through a conventional text book format. In this way the case material developed will be accessible to anyone interested in the ethical and social consequences of commercializing human genome research.